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INTRODUCTION
A state of donor-specific tolerance in organ transplant
recipients would obviate the risks of both acute and chronic
rejection, thus eliminating the need for chronic immuno-
suppressive therapy. This state of specific transplantation
tolerance can be achieved through successful allogeneic
bone marrow engraftment. However, most applications of
this approach have involved the use of lethal whole body
irradiation (WBI) or high doses of total lymphoid irradia-
tion before injection of allogeneic bone marrow cells
(BMCs) [1-3]. Unfortunately, the severe toxic side effects of
such conditioning regimens have precluded their use in
humans as a means of inducing tolerance.
A nonmyeloablative method of conditioning mice for
bone marrow transplantation (BMT) that allows induction of
mixed chimerism and donor-specific tolerance across full
major histocompatibility complex (MHC) barriers has been
described [4]. This nonmyeloablative regimen consists of the
administration of depleting doses of anti-CD4 and anti-CD8
monoclonal antibodies (MoAbs) on day –5 or day –1 and of
3 Gy of WBI and 7 Gy of thymic irradiation (TI) on day 0,
followed by injection of 1.5 × 107 fully MHC-mismatched
allogeneic BMCs. Mice treated in this way develop perma-
nent mixed chimerism and donor-speciﬁc skin allograft tol-
erance [4]. The mechanism of tolerance in these animals
primarily involves the central deletion of donor-reactive T-cell
clones. This deletion results from the presence of donor-
type antigen-presenting cells in the thymus. Maintenance of
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ABSTRACT
A nonmyeloablative conditioning regimen, consisting of depleting doses of anti-CD4 and anti-CD8 monoclonal
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mice, suggesting that residual host thymocytes reject donor marrow in recipients of 1, but not 2, MoAb injections.
In this study, both CD4+ and CD8+ thymocytes were found to be responsible for residual alloreactivity in mice
receiving only 1 MoAb injection. Co-receptor coating and downmodulation on residual thymocytes occur to a
greater extent in recipients of 2 MoAb injections than in recipients of a single MoAb injection. This downmodula-
tion may play a role in the loss of alloreactivity. Our results suggest that a second MoAb injection inactivates
mature, functional donor-alloreactive CD4+ and CD8+ host thymocytes.
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tolerance in this model depends on the continuous intra-
thymic presence of donor hematopoietic cells [5-7].
To make this nonmyeloablative conditioning regimen
more applicable in the clinical setting of organ transplantation,
we have attempted to modify it to further reduce its potential
toxicity. Recently, we reported that the necessity of using TI to
allow permanent mixed chimerism production could be over-
come by administering an additional pre-BMT anti-CD4 and
anti-CD8 T-cell–depleting MoAb injection [8]. When 2 MoAb
injections were given on days –6 and –1 and 3 Gy of WBI was
given on day 0, most animals demonstrated high early levels of
donor T-cell repopulation, lasting mixed chimerism, and
donor-speciﬁc skin graft acceptance [8]. In contrast, when a
single MoAb injection was administered on day –5 or day –1,
administration of TI was essential for the reliable induction of
lasting chimerism and tolerance [4,5,8]. A single administra-
tion of these MoAbs 5 days before BMT leads to almost com-
plete depletion of peripheral T cells in mice. However, despite
the presence of an initially successful hematopoietic graft,
these animals later lose peripheral chimerism. Because TI pre-
vented this delayed marrow rejection and because animals
receiving a single MoAb injection without TI showed a loss of
intrathymic chimerism before the loss of peripheral chimerism
[9], we hypothesized that donor hematopoietic cells might be
rejected intrathymically by residual nontolerant host thymo-
cytes in mice receiving 1 MoAb injection without TI. The T-
cell repertoire developing in the thymus after destruction of
intrathymic donor cells would not be tolerant of donor anti-
gens and, therefore, could subsequently reject donor hemato-
poietic cells in the periphery.
The administration of a second MoAb injection or TI
seems to effectively overcome intrathymic alloresistance.
This result could reflect a greater degree of thymocyte
depletion induced by the second MoAb injection. Alterna-
tively, the beneficial effect of the second MoAb injection
could reﬂect functional effects on residual thymocytes that
result from blocking CD4 and CD8 co-receptors or from
other related effects of high-dose MoAb treatment. To deter-
mine how a second injection of anti-CD4 and anti-CD8
MoAbs before BMT overcomes the requirement for TI, we
compared thymocyte depletion and residual alloreactivity
and co-receptor downmodulation of thymocytes in mice
receiving an insufﬁcient (single) MoAb injection regimen to
those in mice receiving a more successful regimen involving
2 injections of anti–T cell MoAbs before BMT.
MATERIALS AND METHODS
Animals
Female C57BL/6 (B6: H-2b; Kb,I-Ab,I-E-,Db), B10.A
(B10.A: H-2a; Kk,I-Ak,I-Ek,Dd), and SJL (H-2s) mice were
purchased from Harley-Sprague Dawley via the Frederick
Cancer Research Center (Frederick, MD). All mice were
maintained in sterilized microisolator cages and received
autoclaved feed and autoclaved, acidified drinking water.
Recipients in each experiment were age matched and were
aged 10 to 12 weeks.
Conditioning and BMT
Recipient B6 mice were treated with MoAbs intraperi-
toneally on the indicated days (see below). Each injection
consisted of 1.1 mg puriﬁed rat anti-mouse CD4 immuno-
globulin (Ig) G2b MoAb GK1.5 [10] and 1.4 mg puriﬁed rat
anti-mouse CD8 IgG2b MoAb 2.43 [11]. On day 0, WBI
(3 Gy) was administered to MoAb-treated animals, as
described [4]. Four to 6 hours after completion of condi-
tioning on day 0, 1.5 × 107 untreated BMCs from B10.A
mice were administered intravenously.
Flow Cytometric Analysis of Chimerism
The level of allogeneic donor T-cell and non–T-cell
reconstitution was evaluated by 2-color flow cytometric
(FCM) analysis on a FACScan or FACSort (Becton Dickin-
son, Mountain View, CA), as previously described [8].
Brieﬂy, forward angle and 90° light scatter properties were
used to distinguish between lymphocytes, granulocytes, and
monocytes in peripheral white blood cells (WBCs). Two-
color ﬂuorescence-activated cell sorting (FACS) was used to
distinguish between donor and host cells expressing particu-
lar lineage markers. The percentage of donor cells was cal-
culated by subtracting control staining from quadrants
containing donor and host cells expressing a particular lin-
eage marker and by dividing the net percentage of donor
cells by the total net percentage of donor plus host cells of
that lineage. Nonspecific FcγR binding was blocked with
10 µL of undiluted culture supernatant containing rat anti-
mouse FcγR MoAb 2.4G2 [12]. Biotinylated anti-H-2Dd
MoAb 34-2-12 [13] and nonreactive control MoAb HOPC1
were incubated with phycoerythrin-streptavidin (PEA). Flu-
orescein isothiocyanate (FITC)-conjugated MoAbs included
anti-CD4, anti-CD8, and anti-B220 (Pharmingen, San
Diego, CA). Negative control MoAb HOPC1-FITC, which
has no reactivity to mouse cells, was prepared in our labora-
tory. Dead cells were excluded by gating out low forward
scatter/high propidium iodide–retaining cells.
FCM Analysis of Thymocytes
Thymocytes were analyzed with 2- and 3-color FCM,
using anti-CD4 and anti-CD8 MoAbs that are not blocked
by the MoAbs used for in vivo depletion (data not shown).
Thymocytes were stained with biotinylated anti-CD8β
MoAb 53-5.8 and control MoAb HOPC1 and were incu-
bated with PEA for 2-color analysis or with Cy-Chrome
(Pharmingen) for 3-color analysis. Anti-CD4 MoAb RM4-4
was PE-conjugated. FITC-conjugated MoAbs included
anti-pan T cell–receptor (anti-pan TCR) β, anti-heat stable
antigen (HSA) (J11D) [14], anti-Kb MoAb 5F1 [15], and
control MoAb HOPC1 (J11D, 5F1, and control HOPC1
MoAbs were prepared in our laboratory, and the remainder
were purchased from Pharmingen). A minimum of 5000
gated CD4+ or CD8+ single-positive cells were collected for
expression of TCR, HSA, or MHC class I. A minimum of
5000 gated TCRhigh, HSAlow cells or TCRhigh, HSAhigh cells
were collected for analysis of CD4 expression.
Analysis of T-Cell Coating With MoAbs
Mice receiving anti-CD4 and anti-CD8 MoAbs were
tested for the level of thymocyte and splenocyte coating
with MoAb using FCM on various days. Splenocytes and
thymocytes were stained by FITC-conjugated goat anti-rat
IgG MoAb (GAR-F) (Tago Inc., Burlingame, CA). Staining
was compared with that of cells preincubated with 10 µL
B. Nikolic et al.
146
of diluted ascites of GK1.5 (1:400) and/or 2.43 (1:400)
followed by GAR-F. Cells were also stained directly with
PE-conjugated anti-CD4 and anti-CD8 MoAbs (which rec-
ognized distinct epitopes from those recognized by GK1.5
and 2.43) and biotinylated anti-panTCRβ MoAb (Pharmin-
gen) followed by PEA. Double negative thymocytes were
excluded from calculations.
Mixed Lymphocyte Reaction Assay
Splenocyte suspensions were prepared by lysing red
blood cells (RBCs) with ammonium chloride potassium
(ACK) buffer (BioWhittaker, Walkersville, MD) and then
washing and resuspending the remaining cells in RPMI
medium supplemented with 15% (vol/vol) controlled processed
serum replacement (CPSR-2) (Sigma, St. Louis, MO), 4%
nutrient mixture (L-glutamine, nonessential amino acids,
sodium pyruvate, and penicillin/streptomycin), 1% HEPES,
and 10 µmol/L 2-mercaptoethanol. Thymocyte suspensions
were prepared without RBC lysing, and cells were washed
and resuspended in the same medium, with the addition of
10 IU/mL of recombinant human interleukin (rhIL)-2
(Aldesleukin; Chiron, Emeryville, CA). Triplicate wells con-
taining either 4 × 105 responders (splenocytes) or 8 × 105
responders (thymocytes), with 4 × 105 stimulators (30-Gy irra-
diated) in a total volume of 0.2 mL of medium were incubated
at 37°C in 8% CO2. Thymic mixed lymphocyte reaction
(MLR) assays were performed in round-bottomed plates
instead of ﬂat-bottomed plates, which were used for splenic
MLR. Cultures were pulsed with 1 µCi (1 Ci = 37 Gbq) of
3H-thymidine on the fourth or ﬁfth day, harvested on the ﬁfth
or sixth day with a Tomtec automated harvester, and assayed in
a Pharmacia LKB Betaplate. The mean cpm of 3 replicates
was calculated, and data were expressed as stimulation index
(SI), which was calculated as follows: SI = (mean cpm in the
presence of irradiated allogeneic stimulators)/(mean cpm in
the presence of irradiated host-type [B6] stimulators).
Cell-Mediated Lympholysis Assay 
Cell-mediated lympholysis (CML) studies were per-
formed as previously described [16]. Spleens were removed
from BMT recipients and normal mice; RBCs were lysed
using ACK buffer; and single-cell suspensions were pre-
pared. Cells were ﬁltered through 100-mesh nylon, washed,
and resuspended at 8 × 106 cells/mL in complete medium
consisting of RPMI 1640 with 10% fetal calf serum,
0.025 mmol/L 2-ME, 0.01 mol/L HEPES buffer, 0.09 mmol/L
nonessential amino acids, 1 mmol/L sodium pyruvate,
2 mmol/L glutamine, 100 U/mL penicillin, and 100 µg/mL
streptomycin. Thymocyte suspensions were prepared with-
out RBC lysing, and cells were washed and resuspended to
16 × 106 cells/mL in the same medium with 10 IU/mL of
rhIL-2. In each well of 96-well plates, 100 µL of responder
cells were cocultured with 4 × 105 stimulator cells (irradiated
with 30 Gy). Cultures were set up in 2 rows of 3 replicates
each. After 5 days of incubation in 8% CO2 at 37°C, 2-fold
serial dilutions were prepared from the second row of tripli-
cates so that cytolytic capacity could be examined at a total
of 5 different responder-to-target (R:T) ratios. 51Cr-labeled
2-day Concanavalin A–induced lymphoblasts were then
added at 8 × 103 blasts per well and incubated for 4 hours in
8% CO2 at 37°C. Plates were harvested using the Titertek
supernatant collection system (Skatron, Sterling, VA), and
51Cr release was determined with an automated gamma
counter. Percent specific lysis was calculated with the fol-
lowing formula.
% Speciﬁc lysis =
experimental release – spontaneous release
× 100%.
maximum release – spontaneous release
Skin Grafting
Initial skin grafting was performed 39 weeks after BMT,
as previously described [4]. Square full-thickness tail skin
grafts (1 cm2) were prepared from donors and grafted onto
the right and left lateral thoracic wall of recipient mice.
Grafts were inspected on day 7, then daily for the first
month and 2 to 3 times per week thereafter. Rejection of the
grafts was deﬁned as the time of complete sloughing or for-
mation of a dry scab.
Statistical Analysis
Statistical significance was determined using Student
t test. P < .05 was considered statistically signiﬁcant.
RESULTS
Both CD4 and CD8 Single-Positive Thymocytes
Resist Donor Engraftment
A second injection of anti-CD4 and anti-CD8 MoAbs
on day –1 can replace TI and still induce lasting chimerism
and tolerance in mice receiving MoAbs on day –6 and 3 Gy
WBI on day 0 [8]. We hypothesize that additional MoAb
treatment overcomes the capacity of host thymocytes to
reject donor marrow. This rejection was presumably medi-
ated by the more mature host thymocytes, which express
either CD4 or CD8, but not both co-receptors. To deter-
mine whether residual host CD4+ or CD8+ single-positive
thymocytes are responsible for this residual alloreactivity in
mice receiving only 1 MoAb injection, B6 mice received
anti-CD4 and anti-CD8 MoAbs on day –6; on day –1, they
received either no further MoAb treatment or a second
injection of anti-CD4 alone, anti-CD8 alone, or both
MoAbs. On day 0, 3 Gy WBI and 1.5 × 107 B10.A BMCs
were given. Allogeneic repopulation was evaluated 3 weeks
after BMT and at later time points by staining peripheral
WBCs with a MoAb (34-2-12; anti-H-2Dd) that recog-
nizes donor class I MHC. Early and lasting multilineage
chimerism was observed in 5 of 6 recipients treated with
anti-CD4 plus anti-CD8 MoAbs on days –6 and –1, and
with 3 Gy WBI before injection of B10.A BMCs (Figure 1,
top panel) (mean percentage of donor class I+ cells in periph-
eral WBCs was 36.5% at week 3, 41.1% at week 8, and 34.1
at week 18), as described previously [8]. These animals
developed high levels of stable donor T-cell chimerism. In
contrast, omission of the second MoAb injection allowed
the initial development of donor class I + chimerism in 4 of
6 animals, but none of the animals developed long-term
chimerism (Figure 1, top panel) (mean percentage of donor
class I+ cells in WBCs was 16.5% at week 3, 2.4% at week 8,
and 0.5% at week 18). Furthermore, there was no evidence
of T-cell chimerism in any of animals (Figure 1, bottom
panel). These results conﬁrmed previous results indicating
that a second anti-CD4 plus anti-CD8 MoAb injection is
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essential for the consistent induction of lasting chimerism,
and for the induction of T-cell chimerism, in mice that do
not receive TI before BMT [8].
As shown in Figure 1, both MoAbs were required on
day –1 to achieve lasting multilineage chimerism. Injection
of only anti-CD4 MoAb on day –1 was associated with the
initial development of chimerism in all animals, but none of
the animals developed long-term chimerism (mean 34.5%
donor WBCs at week 3, 9.6% at week 8, and 1.1% at week
18). Injection of only anti-CD8 on day –1 led to a similar
outcome, with only 1 of 6 animals becoming a long-term
chimera (mean percentage of donor class I+ cell in WBCs
was 27.3% at week 3, 19.5% at week 8, and 16.8% at week
18). These results suggest that both residual CD4+ and
CD8+ single-positive (SP) thymocytes are capable of reject-
ing donor cells in mice conditioned with a single MoAb
injection and 3 Gy WBI.
Induction of Specific Transplantation Tolerance
To evaluate tolerance in chimeric mice, donor B10.A
and third-party SJL (H-2s) skin was grafted 35 weeks post-
BMT. All grafted animals rejected third-party SJL skin
grafts within 20 days (data not shown). In all recipients (4 of
4) prepared with the regimen that included anti-CD4 and
anti-CD8 MoAbs on day –5 only, plus 3 Gy WBI, the B10.A
skin grafts were rejected within 15 days (Figure 2). In con-
trast, all mice (3 of 3) that received anti-CD4 and anti-CD8
MoAbs on both days –6 and –1, plus 3 Gy WBI, accepted
B10.A skin grafts for >100 days, consistent with previous
results [8]. The administration of only anti-CD4 or only
anti-CD8 MoAb on day –1, in addition to anti-CD4 and
anti-CD8 MoAbs on day –6 and 3 Gy WBI, was not sufﬁ-
cient to allow the induction of skin graft acceptance in the
majority of animals (Figure 2).
Residual Intrathymic, but Not Splenic, Alloreactivity
Persists After a Single MoAb Injection
To evaluate the capacity of splenic and thymic T cells
from conditioned animals to respond to host or donor anti-
gens in vitro, MLR and CML assays were performed on day 6
postirradiation. Treatment with MoAbs on days –6 and –1
plus 3 Gy WBI (which allows alloengraftment in 80% to 90%
of animals) or with MoAbs on day –5 only plus 3 Gy WBI
(which is insufﬁcient conditioning in most animals), resulted
in splenic T-cell MLR (Figure 3, top panel) and CML (Fig-
ure 3, bottom panel) unresponsiveness in all animals tested.
Animals treated with 3 Gy WBI without any MoAb treat-
ment showed significant MLR (Figure 3, top panel) and
CML (Figure 3, bottom panel) responses to B10.A stimula-
tors. These observations were consistent with previous results
indicating that a single MoAb injection and 3 Gy of WBI
results in near-complete peripheral T-cell depletion, despite a
lack of long-term donor-speciﬁc tolerance [4,9].
Figure 4 shows thymic T-cell alloreactivity in MLR (top
panel) and CML (bottom panel) assays performed on these
animals. The conditioning treatment with MoAb injections
on days –6 and –1 and 3 Gy of WBI on day 0 resulted in a
lack of alloresponsiveness of thymocytes, as measured by
Figure 1. Percentage of chimeric animals (top) and percentage of ani-
mals with T-cell chimerism (bottom) in peripheral blood. Donor rep-
resentation among various hematopoietic lineages was determined at
multiple time points after bone marrow transplantation by color ﬂuo-
rescence-activated cell sorting. Animals that had >1% donor class I+ cells
were deﬁned as chimeric. All mice received T-cell depletion  with anti-
CD4 and anti-CD8 monoclonal antibodies (MoAbs) on day –6; 3 Gy
whole body irradiation on, day 0; and 15 × 106 B10.A–bone marrow
cells on day 0. Some animals (n = 7) received no additional treatment
(None). The anti-CD4 and anti-CD8 group (n = 7) received an addi-
tional injection of anti-CD4 and anti-CD8 MoAbs on day –1. The
other groups received an additional injection of anti-CD8 only (n = 6)
or anti-CD4 only (n = 7) on day –1.
Figure 2. Donor B10.A skin graft survival. Skin graft survival is shown
for groups that received anti-CD4 and anti-CD8 monoclonal antibod-
ies (MoAbs) on day –6 and 3 Gy of whole body irradiation followed by
donor bone marrow transplantation on day 0 (None; n = 4). In addi-
tion, some animals received an additional anti-CD4 and anti-CD8
MoAb injection on day –1 (anti-CD4 and anti CD8, n = 3); an addi-
tional anti-CD4 MoAb injection on day –1 (anti-CD4, n = 4); or an
additional anti-CD8 MoAb injection on day –1 (anti-CD8, n = 5). All
animals rejected third-party SJL skin grafts within 20 days (not shown).
Donor B10.A and third-party SJL (H-2s) skin was grafted 39 weeks
after the bone marrow transplantation.
B. Nikolic et al.
148
MLR (Figure 4, top panel) and CML (Figure 4, bottom panel)
assays. In contrast, 3 of 3 studies have shown measurable
CML or MLR alloreactivity in day-6 thymi of animals
receiving a MoAb injection on day –5 only and 3 Gy of WBI
on day 0. Although these MLR and CML responses were
significantly lower than those of untreated controls, they
were statistically significant compared with those of mice
that received MoAbs on days –1 and –6 plus 3 Gy of WBI on
day 0. The ability to demonstrate thymic alloreactivity in
both MLR and CML assays in recipients of MoAbs only on
day –6 is consistent with the observation that both CD4 and
CD8 cells mediate in vivo residual alloreactivity in recipients
of this treatment (Figure 1).
Differences in Thymocyte Coating With MoAbs
To address the mechanism by which injection of a second
dose of depleting MoAbs inactivates alloreactive thymocytes,
the level of MoAb coating on thymocytes and peripheral
T cells of mice treated with 1 or 2 injections of anti-CD4 and
anti-CD8 MoAbs was compared at day 6 postirradiation.
Thymocytes were stained with FITC-conjugated goat anti-
rat IgG MoAb (Figure 5; GαR). Staining was compared with
that of cells preincubated with saturating amounts of GK1.5
and 2.43 followed by FITC-conjugated goat anti-rat IgG
MoAb (Figure 5; αCD4+8, +GαR). The FACS analysis of
thymocytes from animals receiving MoAbs on days –6 and –1
Figure 3. Absence of alloreactivity in spleens of mice treated with 1
or 2 anti-CD4 and anti-CD8 monoclonal antibody (MoAb) injec-
tions and 3 Gy of whole body irradiation (WBI). B6 mice receiving
anti-CD4 and anti-CD8 MoAb injections on day –6 and day –1 (n = 6),
or on day –5 alone (n = 6), followed by 3 Gy of WBI on day 0, were
killed at day 6 postirradiation. Allogeneic mixed lymphocyte reaction
(MLR) and cell-mediated lympholysis (CML) responses of spleno-
cytes isolated from these 2 groups of animals were compared with
responses of splenocytes isolated from untreated B6 mice (none) or
with responses of splenocytes isolated from 3 Gy irradiated B6 mice
(3 Gy). The top panel shows MLR unresponsiveness of splenocytes
isolated from animals treated with either 1 or 2 MoAb injections.
Responder splenocytes were incubated with irradiated B10.A () or
B6 () stimulators for 3 days. Proliferation was assessed by pulsing
with 1 µC of [3H]thymidine on the third day and harvesting on the
fourth day. SD values for triplicates are <20%. *P < .05 for alloreac-
tive response versus anti-B6 response. The bottom panel shows
CML unresponsiveness to B10.A stimulators and targets () or to B6
stimulators and targets () of splenocytes isolated from animals
treated with either 1 or 2 MoAb injections. Percent specific lysis at
the 100:1 responder-to-target ratio is shown. *P < .05 for alloreactive
response versus anti-B6 response. Results shown are representative
of 3 similar experiments.
Figure 4. Residual alloreactivity in thymi of animals treated with a
single monoclonal antibody (MoAb) injection and 3 Gy of whole body
irradiation (WBI). B6 mice that received anti-CD4 and anti-CD8
MoAb injections on day –6 and day –1 (n = 6), or on day –5 alone (n = 6),
followed by 3 Gy of WBI on day 0, were killed at day 6 postirradia-
tion. Allogeneic mixed lymphocyte reaction (MLR) and cell-mediated
lympholysis (CML) responses of thymocytes isolated from these
2 groups of animals were compared with responses of thymocytes iso-
lated from untreated B6 mice (None) or with responses of thymocytes
isolated from 3 Gy irradiated B6 mice (3 Gy). Top panel, MLR
responsiveness of thymocytes isolated from animals treated with 1 (–5,
3 Gy), but not 2 (–6, –1, 3 Gy) MoAb injections. Responder thymo-
cytes were incubated with irradiated B10.A () or B6 () stimulators
for 4 days, as described in Materials and Methods. *P < .05 for allore-
active response versus anti-B6 response. The bottom panel shows that
CML responsiveness persists after a single MoAb injection. Percent
speciﬁc lysis for 100:1 responder-to-target ratio is shown. *P < .05 for
alloreactive response versus anti-B6 response. Results shown are rep-
resentative of 3 experiments.
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and 3 Gy of WBI on day 0 demonstrated no significant
change in the intensity of staining after preincubation with
saturating amounts of anti-CD4 and anti-CD8 MoAbs, indi-
cating that thymocytes were completely coated with these
MoAbs in vivo (Figure 5; Days –6 and –1 thymocytes). In
contrast, when a single MoAb injection was administered on
day –5, a shift in the intensity of staining was observed after
the addition of GK1.5 and 2.43 in vitro, indicating that thy-
mocyte CD4 and CD8 molecules were not saturated with
antibodies in vivo (Figure 5; Day –5 thymocytes). No differ-
ence in the intensity of staining was observed for day 6
splenocytes treated with 1 or 2 MoAbs injections (not shown).
Next, we performed a kinetic study on thymocyte and
splenocyte coating. As shown in Figure 6 (top panel), there
was a signiﬁcant difference between the groups in thymocyte
coating on days 6, 8, 13, and 18 post-WBI. This difference
was greatest on days 8 and 13 post-WBI. In mice conditioned
with MoAbs on day –5 and with 3 Gy of WBI, <50% of thy-
mocytes were coated with MoAbs on day 8, but nearly 100%
of thymocytes in recipients of MoAbs on days –6 and –1 plus
3 Gy of WBI on day 0 were coated with MoAbs. We
observed a signiﬁcant difference between these 2 groups in
the percentage of coated splenic T cells only at 18 days post-
WBI (Figure 6, bottom panel). Thus, a more marked early
difference was observed between the 2 groups in thymocyte
than in splenocyte coating with MoAbs. These results show
an association between incomplete thymocyte coating with
MoAbs and the presence of MLR and CML responses among
thymocytes of mice treated with MoAbs only on day –5.
Residual Thymocytes Downmodulate TCR and CD4
Co-Receptor to a Greater Extent in Recipients of
2 MoAb Injections
We compared the numbers of double-negative, double-
positive, and CD4 and CD8 SP thymocytes on day 6 in
recipients of either of the MoAb treatment protocols plus
3 Gy of WBI. A small but statistically nonsigniﬁcant differ-
ence was observed in the overall level of thymocyte deple-
tion between recipients of these 2 regimens (in 3 experi-
ments, the mean thymocyte counts for 4 to 6 mice per
group receiving MoAbs on day –5 versus on days –6 and –1
were 39.7 × 106 versus 26.9 × 106, respectively; 51 × 106 ver-
sus 34.4 × 106, respectively; and 50.8 × 106 versus 43.2 ×
106, respectively; P > .1). Furthermore, no statistically
signiﬁcant difference was observed in the percentages of dif-
ferent thymic subpopulations (CD4+CD8–, CD4–CD8+,
Figure 5. Incomplete thymocyte coating with monoclonal antibodies
(MoAbs) of mice treated with MoAbs on day –5 only. Mice that
received anti-CD4 and anti-CD8 MoAbs were tested for the level of
thymocyte coating with MoAb using ﬂow cytometry on day +6. Fluo-
rescence-activated cell sorting analysis of thymocytes is shown for non-
treated B6 animals (CTRL) and for animals receiving anti-CD4 and
anti-CD8 MoAbs on days –6 and –1 (Days –6, –1) or on day –5 (Day –5)
and 3 Gy of whole body irradiation on day 0. Thymocytes were stained
by fluorescein isothiocyanate (FITC)–conjugated goat anti-rat IgG
MoAb (GαR). Staining was compared with that of cells preincubated
with 10 µL of a saturating amount of GK1.5 and 2.43 followed by
FITC-conjugated goat anti-rat IgG MoAb (αCD4+8, +GαR). The ﬁg-
ure shows a representative result from 15 animals tested at day 6.
Figure 6. Differences in thymocyte coating are evident at earlier time
points than are the differences in splenocyte coating in mice receiving
1 versus 2 monoclonal antibody (MoAb) injections. The percentage of
coated T cells in the thymi (top panel) and spleens (bottom panel) is
shown for animals receiving anti-CD4 and anti-CD8 MoAbs on day
–5 ( ) or on days –6 and –1 ( ), plus 3 Gy of whole body
irradiation on day 0. For each time point, the mean of 2 to 4 animals is
shown. *P < .05.
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CD4+TCRhighHSAlow, and CD8+TCRhighHSAlow) between
recipients of these 2 regimens (data not shown). In separate
experiments, we performed a kinetic study on thymocyte
depletion (Table). No statistically signiﬁcant difference was
observed in the level of thymocyte depletion between recipi-
ents of these 2 regimens on days –3/–2, 4, 8, or 12 (Table).
Therefore, we investigated whether the differing effects of
the 2 MoAb regimens might be related to TCRαβ or CD4
or CD8 co-receptor downmodulation. We used 2- and 3-color
FCM analysis to focus on the more mature, HSAlowTCRhigh
thymocyte subpopulations [17-19]. By 2-color FCM analy-
sis, we compared TCRαβ downmodulation at days 1, 4, 6,
and 8 following 3 Gy of WBI. As shown in Figure 7, expres-
sion of TCRαβ on mature thymocytes was similarly down-
modulated in both groups on days 1, 4, and 6 following 3
Gy of WBI. However, the intensity of TCR staining on day
8 thymocytes was significantly more reduced in animals
receiving 2 MoAb injections than in those receiving MoAbs
on day –5 alone (plus 3 Gy of WBI).
By 3-color FCM analysis, we compared CD4 downmod-
ulation among mature thymocytes on days 4, 6, 8, and 12 fol-
lowing 3 Gy of WBI. CD4 expression on mature thymocytes
was similar in both groups on days 4 and 12 (not shown). How-
ever, the intensity of CD4 staining on day 8 mature CD4+ SP
thymocytes was signiﬁcantly more reduced (P < .01) in ani-
mals receiving 2 MoAb injections (mean ± SD, 34.4 ± 3.1
median ﬂuorescence intensity [MFI] for HSAlowTCRhigh pop-
ulation) than in those receiving MoAbs on day –5 only
(plus 3 Gy WBI) (mean ± SD, 61.0 ± 9.9 MFI for HSAlowT-
CRhigh population). Figure 8 shows a representative FCM
profile for day 8 thymocytes. Significantly more CD4
downmodulation (P < .05) was also observed for the some-
what less mature HSAhighTCRhigh population in mice receiving
2 MoAb injections (mean ± SD, 66.8 ± 14.2 MFI) compared
with those receiving a single MoAb treatment (mean ± SD,
80.6 ± 21.2 MFI). Similarly, in animals killed on day 6 post-
WBI, when functional analyses were conducted, the group
receiving a single MoAb treatment demonstrated signifi-
cantly less downmodulation of CD4 in the HSAhighTCRhigh
population (mean ± SD, 38.4 ± 3.2 MFI) than did the group
receiving 2 MoAb injections (mean ± SD, 29.08 ± 2.3 MFI).
However, the degree of CD4 downmodulation in the HSA-
lowTCRhigh populations was similar between these 2 groups on
day 6 post-WBI.
Although thymocytes in both groups demonstrated
significant downmodulation of the CD8 co-receptor com-
pared with thymocytes of normal B6 control mice, on day 6
we did not observe any signiﬁcant difference in CD8 down-
modulation between groups of animals receiving 2 MoAb
injections compared with those receiving MoAbs on day –5
alone (plus 3 Gy of WBI) (data not shown).
DISCUSSION
We demonstrate here that in mice receiving insufﬁcient
MoAb treatment before BMT, initial central tolerance may
be precluded by a failure to adequately inactivate residual
host CD4 and CD8 SP thymocytes. These residual host-
derived alloreactive thymocytes mediate intrathymic rejec-
tion of donor cells, even if peripheral chimerism has been
initially established, and lead to the development of a non-
tolerant T-cell repertoire and eventual rejection of the
peripheral marrow allograft [9]. Determination of the
residual thymocyte functions that must be inactivated and
the mechanism by which this can be achieved will be essen-
tial to the extension of this approach to other species. The
results presented here advance our effort to develop a more
specific, targeted approach to recipient conditioning that
utilizes the minimal amount of myelosuppression and
immunosuppression required to permit partial reconstitu-
tion by an allogeneic marrow donor.
Cell Depletion in the Thymi of B6 Mice*
Day Before/After 3 Gy
Treatment –3/–2† 4 8 12
None‡ 66.4 70 74 63.6
–5, 3 Gy§ 33.6 2.0 ± 0.7 29.4 ± 8.9 73.7 ± 23.8
–6, –1, 3 Gy¶ 33.6 2.5 ± 0.9 29.0 ± 11.1 63.1 ± 21.1
*Mice were killed at different time points, and thymocytes were
counted in a single cell suspension. The mean number of cells 106 is
shown for each group (n = 1 per group/per day –3 or –2; n = 3-4 mice per
group/per days 4, 8, and 12). Similar results were obtained in 2 different
experiments.
†Recipients of day –5 monoclonal antibodies (MoAbs) were killed
on day –2, and recipients of day –6 and –1 MoAbs were killed on day –3.
‡Untreated age-matched control B6 mice.
§B6 mice were pretreated with anti-CD4 plus anti-CD8 MoAbs on
day –5 and with 3 Gy of whole body irradiation (WBI) on day 0.
No statistical difference (P > .05) was observed in the level of thy-
mocyte depletion between recipients of these 2 regimens.
¶B6 mice were pretreated with anti-CD4 plus anti-CD8 MoAbs on
days –6 and –1 and with 3 Gy of WBI on day 0.
Figure 7. Prolonged downmodulation of T-cell receptor (TCR) in
recipients of 2 monoclonal antibody (MoAb) injections. Thymocytes
were analyzed with 2-color ﬂow cytometry. A minimum of 5000 gated
TCRhigh heat stable antigen (HSA)low cells were collected and analyzed.
The relative median fluorescence intensity (MFI) was calculated by
dividing the observed MFI of the peak of cells staining with anti-
TCRαβ among gated TCRhighHSAlow cells from experimental animals
by the observed MFI of the same cell population from normal B6 mice.
Animals received anti-CD4 and anti-CD8 MoAbs on day –5 ( )
or anti-CD4 and anti-CD8 MoAbs on days –6 and –1 ( ), fol-
lowed by 3 Gy of whole body irradiation on day 0. For each time point,
the mean of 3 animals’ MFI is shown. *P < .05.
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The ability of residual host thymocytes to reject donor
hematopoietic cells can be overcome by an additional MoAb
treatment. To achieve lasting chimerism and tolerance, both
CD4+ and CD8+ SP thymocytes must be targeted by this sec-
ond treatment. The thymus contains a number of SP thymo-
cytes, located mostly within the thymic medulla, and because
these mature T cells have the potential to respond to
alloantigens and because thymic dendritic cells and B cells
have antigen-presenting functions, it is possible that host-
versus-graft alloreactivity could occur in the thymic environ-
ment. Intrathymic rejection in mice receiving inadequate
MoAb treatment may be directed at donor thymocytes, den-
dritic cells, or their common progenitors [20]. Consistent
with the possibility of host-versus-graft alloreactivity, we
identiﬁed an animal in the single MoAb treatment group that
showed a relatively high level of peripheral chimerism at day
14, but which did not show detectable donor-type thymo-
cytes or class II+ cells in the thymus, and in which intrathymic
deletion of Vβ11+ cells was not evident [9]. Furthermore, in
animals receiving only anti-CD4 or anti-CD8 or neither
MoAb on day –1 (plus both MoAbs on day –5 and 3 Gy of
WBI), initial chimerism was seen in the periphery at similar
levels in all groups. However, only the group receiving both
anti-CD4 and anti-CD8 MoAbs on day –1 showed lasting
chimerism and developed T-cell chimerism (Figure 1). These
results are consistent with the interpretation that the addi-
tional injections of both MoAbs were required to overcome
intrathymic alloreactivity that would otherwise cause
intrathymic rejection of donor cells, with a consequent fail-
ure to develop T-cell chimerism, as well as delayed rejection
of peripherally engrafted donor cells when nontolerant host
T cells emigrate from the thymus.
We have recently demonstrated that pretreatment of
recipients with cyclosporin A (CYA) can overcome the
requirement for TI or for an additional dose of depleting
anti-CD4 and anti-CD8 MoAbs to achieve consistent allo-
geneic marrow engraftment, mixed chimerism, and speciﬁc
transplantation tolerance [21]. A mechanism by which CYA
may facilitate donor cell engraftment is through the depletion
of SP mature thymocytes. CYA pretreatment–induced deple-
tion or inactivation of mature alloreactive SP thymocytes may
enhance early donor thymic repopulation and induction of
permanent tolerance by depleting the SP thymocytes that are
presumably responsible for this residual thymic alloreactivity
in recipients of a single MoAb injection (Figure 4). Similarly,
we have recently shown that the second MoAb injection or
TI can be replaced by costimulatory blockade. Both cytotoxic
T lymphocyte–associated-4 antigen (CTLA4) Ig and anti-
CD154, used as single agents or in combination, can replace
TI or prolonged T-cell depletion, presumably by blocking
activation of alloreactive thymocytes [22].
In the present studies, no significant difference in the
overall level of thymocyte depletion or in the level of deple-
tion of different thymic subpopulations was observed
between recipients of 1 or 2 MoAb treatments. The inacti-
vation of residual alloreactive CD4 SP thymocytes by a sec-
ond injection of MoAbs may be related to CD4 co-receptor
downmodulation. Downmodulation of CD4 has previously
been shown to occur within 16 hours of GK1.5 administra-
tion, but longer follow-up was not performed [23]. In our
Figure 8. Downmodulation of the CD4 co-receptor in recipients of 2 versus 1 monoclonal antibody (MoAb) injection. Left, The gates used for deﬁni-
tion of J11D (heat stable antigen [HSA])-low and -high and T cell–receptor (TCR)-high cells are shown. The cells that were lowest for J11D expression
were excluded from analysis because they include mainly cells that do not express CD4 or CD8. Right, CD4 downmodulation on day 8 on mature J11D
(HSA)-low, TCR-high and on less mature J11D-high, TCR-high CD4+ thymocytes of mice receiving MoAbs on day –5 and 3 Gy whole body irradia-
tion on day 0 (lower panels) and in mice receiving MoAbs on days –6 and –1 and 3 Gy on day 0 (middle panels). Thymocytes were analyzed with 2- and
3-color ﬂow cytometry using anti-CD4 and -CD8 MoAbs that are not blocked by the MoAbs used for in vivo depletion. Data for an untreated control
mouse are shown in the top panels. Numbers shown on each panel are median ﬂuorescence intensity for the marked peak (middle panels) or for the
entire histogram (right panels). In each group, 3 to 5 animals were analyzed separately. Results shown are representative of 3 similar experiments. 
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study, we have observed CD4 downmodulation and coating
to a greater extent in thymocytes of mice receiving 2 MoAb
injections than in recipients of a single injection (Figure 7).
SP thymocytes can be divided into at least 2 separate
groups: those expressing high levels of HSA (immature) and
those expressing low levels of HSA (mature). It has been
reported that HSAhigh and HSAlow SP thymocytes are similar
to mature T cells in terms of concanavalin A–proliferative
responses and cytotoxic activity [24-26] and in the ability to
induce lethal graft-versus-host disease directed against
minor histocompatibility antigen disparities [27]. We
observed a greater reduction in CD4 levels in both CD4 SP
subpopulations in recipients of 2 versus 1 MoAb treatment.
This downmodulation may play a role in the inactivation
of residual thymocytes in BMT recipients. The decreased
expression of TCR and CD4 co-receptors might result in
decreased signal intensity through the TCR. Although we
have observed a lack of residual intrathymic CD4 and CD8
cell-mediated alloreactivity and a greater degree of CD4 and
TCR downmodulation in the recipients of 2 MoAb injec-
tions than in recipients of a single MoAb injection, such an
increase in downmodulation of the CD8 co-receptor was not
observed. These results suggest that the mechanism of toler-
ance induction in CD4 T cells may differ from that observed
in CD8 T cells, and warrants further investigation.
Overall, our studies indicate that speciﬁc measures are
required to inactivate alloreactive host CD4+ and CD8+ thy-
mocytes to allow donor progenitors to repopulate the recipi-
ent thymus at high levels. High levels of donor hematopoietic
cell engraftment in the host thymus result in permanent
chimerism and a robust state of central deletional tolerance.
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